Your AI-Trained Oncology Knowledge Connection!

Robert J. Motzer, MD

home / authors / robert-j-motzer-md

Articles

Evolving Treatment Landscape of RCC: Future Directions in Care

Brian I. Rini, MD;Moshe Ornstein, MD, MA;Elizabeth R. Plimack, MD, MS;Robert J. Motzer, MD

September 12th 2023

Closing out their program on renal cell carcinoma management, key opinion leaders share closing thoughts on emerging therapies and how the field is evolving.

Frontline IO-Based Regimens in Sarcomatoid or Rhabdoid Metastatic nccRCC

Brian I. Rini, MD;Moshe Ornstein, MD, MA;Elizabeth R. Plimack, MD, MS;Robert J. Motzer, MD

September 5th 2023

Centering discussion on sarcomatoid and rhabdoid non-clear cell renal cell carcinoma, panelists consider frontline IO-based regimens and their value in this setting.

Chromophobe RCC and Papillary Kidney Cancer: Novel Treatment Strategies

Brian I. Rini, MD;Moshe Ornstein, MD, MA;Elizabeth R. Plimack, MD, MS;Robert J. Motzer, MD

September 5th 2023

A brief discussion centered on optimal treatment strategies for patients with chromophobe or papillary kidney cancers.

Non-Clear Cell Renal Cell Carcinoma: Interpreting Data With IO/TKI Combination Therapies

Brian I. Rini, MD;Moshe Ornstein, MD, MA;Elizabeth R. Plimack, MD, MS;Robert J. Motzer, MD

August 29th 2023

Key opinion leaders in the field of renal cell carcinoma management reflect on recent data with IO/TKI combination therapy in patients with non-clear cell disease.

Updates from ASCO 2023: KEYNOTE-B61 Study in Non-Clear Cell Renal Cell Carcinoma

Brian I. Rini, MD;Moshe Ornstein, MD, MA;Elizabeth R. Plimack, MD, MS;Robert J. Motzer, MD

August 29th 2023

Switching its focus to non-clear cell RCC, the panel reviews data presented at ASCO 2023 on KEYNOTE-B61, combining lenvatinib + pembrolizumab in this setting.

Factors Aiding in the Selection of Frontline Therapy in Advanced Clear Cell RCC

Brian I. Rini, MD;Moshe Ornstein, MD, MA;Elizabeth R. Plimack, MD, MS;Robert J. Motzer, MD

August 22nd 2023

Panelists shed light on key factors that help to inform the selection of frontline therapy in patients with advanced clear cell renal cell carcinoma.

Selecting Frontline Therapy for Patients With Advanced Clear Cell RCC

Brian I. Rini, MD;Moshe Ornstein, MD, MA;Elizabeth R. Plimack, MD, MS;Robert J. Motzer, MD

August 22nd 2023

In the context of the available frontline treatment armamentarium for advanced clear cell RCC, key opinion leaders consider how they would select or sequence therapy.

Advanced Clear Cell RCC: Impact of the CLEAR Trial on Real-World Practice

Brian I. Rini, MD;Moshe Ornstein, MD, MA;Elizabeth R. Plimack, MD, MS;Robert J. Motzer, MD

August 15th 2023

Expert panelists consider how updated data from the CLEAR trial of lenvatinib + pembrolizumab in advanced clear cell RCC have impacted their real-world clinical practice.

Data From KCRS 2023: The CLEAR and TRAVERSE Studies in Advanced Clear Cell RCC

Brian I. Rini, MD;Moshe Ornstein, MD, MA;Elizabeth R. Plimack, MD, MS;Robert J. Motzer, MD

August 15th 2023

Centering discussion on the KCRS 2023 annual meeting, experts in renal cell carcinoma elucidate data from the CLEAR and TRAVERSE studies in clear cell disease.

Cabozantinib Plus Nivolumab and Ipilimumab for Advanced Non-Clear Cell RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

August 9th 2023

Experts discuss recent data on a triplet combination therapy for patients with advanced non-clear cell renal cell carcinoma.

Recent Data Updates in the Treatment of Non-Clear Cell RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

August 9th 2023

Drs Robert Motzer and Moshe Ornstein discuss the results of the KEYNOTE-B61 study in patients with non-clear cell renal cell carcinoma.

Emerging Advancements in the Treatment of Clear Cell RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

August 2nd 2023

The panel highlights novel agents under investigation for the treatment of clear cell renal cell carcinoma.

Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Metastatic RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

August 2nd 2023

Moshe Ornstein, MD, reviews the design and efficacy and safety data from the phase 3 CONTACT-03 study in metastatic renal cell carcinoma.

Managing Adverse Events in Patients With Advanced RCC Receiving an IO/TKI Combination Regimen

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

July 28th 2023

Dr Moshe Ornstein details the adverse events seen with IO/TKI combination regimens in patients with advanced renal cell carcinoma and the best strategies for management.

Treating Patients With Metastasized RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

July 28th 2023

Experts discuss the optimal treatment of patients with renal cell carcinoma and brain, bone, or lung metastases.

Selecting an Appropriate Frontline Treatment Regimen for Patients With Advanced RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

July 19th 2023

Moshe Ornstein, MD, explains how he selects a frontline IO/TKI combination regimen for a patient with advanced renal cell carcinoma.

Comparing IO/TKI and IO/IO First-Line Treatment Regimens in Advanced RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

July 19th 2023

Dr Brian Rini shares his view on the data comparing IO/TKI and IO/IO combination regimens for the treatment of advanced renal cell carcinoma.

Pembrolizumab Plus Axitinib Versus Sunitinib for First-Line Treatment of Advanced Clear Cell RCC

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

July 12th 2023

Brian Rini, MD, reviews data from the 5-year analysis of the KEYNOTE-426 trial in advanced clear cell renal cell carcinoma.

Lenvatinib Plus Pembrolizumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma (aRCC)

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

July 12th 2023

Robert Motzer, MD, presents the overall survival analysis data from the 4-year follow-up of the CLEAR study in patients with advanced renal cell carcinoma.

Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Brian I. Rini, MD;Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

May 2nd 2022

Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.

The Exciting Future of Advanced Renal Cell Carcinoma Management

Marie Carlo, MD;Mehmet Asim Bilen, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

May 2nd 2022

A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.

Unmet Needs in Advanced Renal Cell Carcinoma Management

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

May 2nd 2022

Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.

Renal Cell Carcinoma: Future Directions in Care

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

May 2nd 2022

Closing out their discussion on renal cell carcinoma management, experts highlight unmet needs and look toward the future treatment landscape.

Treatment Strategies for Patients Who Progress on Adjuvant Pembrolizumab

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

May 2nd 2022

Following the advent of adjuvant pembrolizumab in high-risk renal cell carcinoma, experts consider treatment strategies for patients who progress on adjuvant pembrolizumab.

Is Adjuvant Pembrolizumab Standard of Care in Patients at Risk of Recurrence?

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

April 25th 2022

Considerations for whether adjuvant pembrolizumab is the new standard of care for patients with renal cell carcinoma at intermediate or high risk of recurrence.

Patient Profile 3: RCC Treated With Adjuvant Pembrolizumab Postnephrectomy

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

April 25th 2022

Expert panelists review a clinical scenario of renal cell carcinoma managed with adjuvant pembrolizumab postnephrectomy based on results of the KEYNOTE-564 trial.